

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Catherine ROUGEOT, et al.

GAU:

SERIAL NO: New Application

EXAMINER:

FILED: Herewith

FOR: THERAPEUTIC USE OF THE SMR1 PROTEIN AND ACTIVE DERIVATIVES THEREOF

REQUEST FOR PRIORITY

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

☒ Full benefit of the filing date of U.S. Application Serial Number 09/367,703, filed October 13, 1999, which is the National Stage of International Application No. PCT/EP98/00956, filed on February 19, 1998, is claimed pursuant to the provisions of 35 U.S.C. §120.

☐ Full benefit of the filing date(s) of U.S. Provisional Application(s) is claimed pursuant to the provisions of 35 U.S.C. §119(e): Application No. Date Filed

☒ Applicants claim any right to priority from any earlier filed applications to which they may be entitled pursuant to the provisions of 35 U.S.C. §119, as noted below.

In the matter of the above-identified application for patent, notice is hereby given that the applicants claim as priority:

COUNTRY

USA

APPLICATION NUMBER

08/801,405

MONTH/DAY/YEAR

February 20, 1997

Certified copies of the corresponding Convention Application(s)

☐ are submitted herewith

☐ will be submitted prior to payment of the Final Fee

☐ were filed in prior application Serial No. filed

☒ were submitted to the International Bureau in PCT Application Number PCT/EP98/00956, filed on February 19, 1998. Receipt of the certified copies by the International Bureau in a timely manner under PCT Rule 17.1(a) has been acknowledged as evidenced by the attached PCT/IB/304.

☐ (A) Application Serial No.(s) were filed in prior application Serial No. filed ; and


☐ (B) Application Serial No.(s)

☐ are submitted herewith

☐ will be submitted prior to payment of the Final Fee

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


Norman F. Oblon

Registration No. 24,618



22850